Compare Aegon Ltd. (AEG) vs Alcon AG (ALC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Alcon AG — how do they compare? Aegon Ltd. trades at $9.37 (market cap $14.00B), while Alcon AG trades at $74.68 (market cap $35.29B). The key difference: Alcon AG is far larger — about 2.5× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.93%). Which is the better fit depends on your goals.
| AEG | ALC | |
|---|---|---|
Market Cap | $14.00B | $35.29B |
Sector | Financials | Health |
52-Week High | $9.53 | $90.12 |
52-Week Low | $6.79 | $62.02 |
Enterprise Value | $15.15B | $39.13B |
Dividend Yield | 4.93% | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.38, showing minimal daily movement with a slight decline of 0.11%. The stock maintains a bullish technical signal with strong moving average support, while oscillators remain neutral. Fundamentally, the company demonstrates improving profitability with a 3.64% net income margin and 9.95% ROE, supported by recent earnings beats in Q2 and Q3 2025. Recent strategic developments include a major $380 billion middle office mandate and governance restructuring as the company transitions to a US-focused model.
AEG presents a mixed investment case with reasonable valuation metrics (P/E 13.57, P/S 0.58) and improving balance sheet health, though cash flow volatility and competitive pressures remain concerns. The analyst consensus leans cautious with 50% hold ratings, suggesting potential for moderate upside if the company's US transition and operational improvements continue successfully.
ALC trades at $73.52, down 2.43% on the day, with a bullish technical signal from moving averages. Recent Q2 2026 earnings beat estimates, and the company raised its 2026 profitability outlook. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. The stock is supported by strong analyst consensus, with a price target of $85.85.
Outlook is positive due to earnings beats and raised guidance, but high P/E of 56.17 poses valuation risk. Competition and margin pressures are key concerns. Institutional interest is rising, with Bill Ackman's new position noted in August 2026 news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →
